| Literature DB >> 25249016 |
Giuseppe Ippolito1, Maria Rosaria Capobianchi1, Simone Lanini1, Guido Antonelli2.
Abstract
Hepatitis C virus (HCV), identified approximately 25 years ago, is recognised as the cause of several clinical conditions besides chronic hepatitis. New compounds with direct antiviral activity have recently been introduced. These drugs promise to outdo old therapies based on interferon and ribavirin both in terms of improved safety and virological response. In fact, these drugs may pave the way to complete eradication of the disease. However, their actual price is exceedingly high and a strategy is necessary to guarantee wide and sustainable access to new therapies.Entities:
Keywords: Antiviral therapy; HCV; Hepatitis C virus
Mesh:
Substances:
Year: 2014 PMID: 25249016 DOI: 10.1016/j.ijantimicag.2014.09.001
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN: 0924-8579 Impact factor: 5.283